Catalyst
Slingshot members are tracking this event:
Novartis' (NVS) PKC412 for Newly-Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) Designated Breakthrough Therapy by FDA
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NVS |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 19, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Pkc412, Newly-diagnosed, Flt3-mutated Acute Myeloid Leukemia, Fda, Breakthrough Therapy Designation
